visualizations
Mekhail, Tarek M., MD
Overview
overview
- Dr. Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd is board-certified in internal medicine, hematology and oncology. Dr. Mekhail serves as medical director of the Thoracic Cancer Program at the Florida Hospital Cancer Institute. He joined the team from the Cleveland Clinic where he was the director of the Lung Cancer Medical Oncology Program. Dr. Mekhail completed his medical degree at Cairo University in 1988, then went on to complete his medical training in the United Kingdom, where he earned fellowships of the Royal College of Surgeon of Edinburgh and Ireland. He completed his medical oncology fellowship at the Cleveland Clinic in Cleveland, Ohio. He is an associate professor at the University of Central Florida. Dr. Mekhail's extensive experience in the field of lung cancer is bolstered by his many awards, including being voted one of the Best Doctors in America in 2007-2008, 2008-2009 and 2009-2010.
research areas
- Cardiovascular System & Cardiology
- General & Internal Medicine
- Health Care Sciences & Services
- Medical Laboratory Technology
- Oncology
- Otorhinolaryngology
- Pathology
- Pharmacology & Pharmacy
- Radiology, Nuclear Medicine & Medical Imaging
- Rehabilitation
- Research & Experimental Medicine
- Respiratory System
Affiliation
Member of
-
Research Department
Publications
Most Recent Publications
-
2024Patient Preferences for EGFR Exon 20 Insertion-Targeted Therapies in NSCLC: A Multi-Dimensional Thresholding Analysis. JOURNAL OF THORACIC ONCOLOGY. E60-E61.
-
2024Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. JOURNAL OF THORACIC ONCOLOGY. 19:941-953.Full Text via DOI: 10.1016/j.jtho.2023.12.023 PMID: 38159809
-
2024Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity. ORAL ONCOLOGY. 154.Full Text via DOI: 10.1016/j.oraloncology.2024.106855 PMID: 38788337
-
2023Molecular Characterization of Non-small Cell Lung Cancer in People Living with HIV or Solid Organ Transplants. JOURNAL OF THORACIC ONCOLOGY. S439-S440.
-
2023Perception of Benefits and Risks of Treatments in Patients with Metastatic NSCLC with EGFRex20ins. JOURNAL OF THORACIC ONCOLOGY. S401-S402.
-
2023Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort. JOURNAL OF CLINICAL MEDICINE. 12.Full Text via DOI: 10.3390/jcm12010112 PMID: 36614913
-
2022Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer. EXPERT REVIEW OF ANTICANCER THERAPY. 95-106.Full Text via DOI: 10.1080/14737140.2023.2157815 PMID: 36537204
-
2022GEMSTONE-302: "If you keep doing the same thing you get the same result". CHINESE CLINICAL ONCOLOGY.Full Text via DOI: 10.21037/cco-22-103 PMID: 36408544
-
2022A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors. JOURNAL OF IMMUNOTHERAPY. 45:389-395.Full Text via DOI: 10.1097/CJI.0000000000000440 PMID: 36066505
-
2022Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is it an Indolent Phenomenon or a More Ominous Pathologic Process?. AMERICAN JOURNAL OF SURGICAL PATHOLOGY. 1592-1594.Full Text via DOI: 10.1097/PAS.0000000000001891 PMID: 35838640
-
2022Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP). ANNALS OF ONCOLOGY. S1004-S1004.Full Text via DOI: 10.1016/j.annonc.2022.07.1115
-
2022Mobocertinib (TAK-788) in metastatic EGFR Exon 20 Insertions (ex20ins) + NSCLC: Results of platinum-experienced Patients and the EXCLAIM Cohort of a Phase 1/2 Study. ONCOLOGY RESEARCH AND TREATMENT. 96-97.
-
2022PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY. S487-S488.
-
2022Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC. JTO CLINICAL AND RESEARCH REPORTS. 3.Full Text via DOI: 10.1016/j.jtocrr.2022.100367 PMID: 35875467
-
2022Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. NATURE MEDICINE.Full Text via DOI: 10.1038/s41591-022-01754-x PMID: 35422531
-
2021Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS >= 1% (LEAP-007): A phase III, randomized, double-blind study. ANNALS OF ONCOLOGY. S1429-S1430.Full Text via DOI: 10.1016/j.annonc.2021.10.139
-
2021A PHASE 1B/2 UMBRELLA STUDY OF ANTI-PD-1 SASANLIMAB IN COMBINATION WITH OTHER THERAPIES FOR PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC): THE LANDSCAPE 1011 TRIAL IN PROGRESS. JOURNAL FOR IMMUNOTHERAPY OF CANCER. A484-A484.Full Text via DOI: 10.1136/jitc-2021-SITC2021.456
-
2021Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy. CLINICAL LUNG CANCER. E856-E858.Full Text via DOI: 10.1016/j.cllc.2021.04.010 PMID: 34119437
-
2021Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort. JOURNAL OF THORACIC ONCOLOGY. S960-S961.
-
2021Mobocertinib in EGFR Exon 20 InsertionePositive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy. JOURNAL OF THORACIC ONCOLOGY. S873-S874.
-
2021Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy. JOURNAL OF THORACIC ONCOLOGY. S960-S960.
-
2021Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. CANCER DISCOVERY. 11:1688-1699.Full Text via DOI: 10.1158/2159-8290.CD-20-1598 PMID: 33632775
-
2021A Rare Case of Primary Cardiac Lymphoma with Extensive Myocardial Invasion And High-Grade Right Ventricular Outflow Tract Obstruction Demonstrating a Complete Metabolic Response to Chemotherapy. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
-
2021Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations. JOURNAL OF THORACIC ONCOLOGY. S108-S108.
-
2021Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors. ANNALS OF ONCOLOGY. S671-S672.Full Text via DOI: 10.1016/j.annonc.2021.08.1156
-
2020Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins). ANNALS OF ONCOLOGY. S815-S816.Full Text via DOI: 10.1016/j.annonc.2020.08.1575
-
2020Fat-Finding Mission: Primary Pleomorphic Liposarcoma of the Heart and Pericardium.. JACC. Case reports. 1520-1526.Full Text via DOI: 10.1016/j.jaccas.2020.05.099 PMID: 34317009
-
2020Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma. CLINICAL LUNG CANCER. 22:E506-E511.Full Text via DOI: 10.1016/j.cllc.2020.07.004 PMID: 32807653
-
2020Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study. SUPPORTIVE CARE IN CANCER.Full Text via DOI: 10.1007/s00520-020-05459-0 PMID: 32318871
-
2019New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting. JOURNAL OF THORACIC ONCOLOGY. S1018-S1019.
-
2019Phase 3, Randomized, Double-Blind Trial of First-Line Pembrolizumab With or Without Lenvatinib in Metastatic NSCLC: LEAP-007. JOURNAL OF THORACIC ONCOLOGY. S405-S405.
-
2019Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). JOURNAL OF NEURO-ONCOLOGY. 144:303-311.Full Text via DOI: 10.1007/s11060-019-03227-7 PMID: 31392595
-
2019Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. LANCET ONCOLOGY. 20:924-937.Full Text via DOI: 10.1016/S1470-2045(19)30167-6 PMID: 31122901
-
2019Effect of early nutrition intervention on advanced nasopharyngeal carcinoma patients receiving chemoradiotherapy.. JOURNAL OF CLINICAL ONCOLOGY.
-
2019The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma.. JOURNAL OF CLINICAL ONCOLOGY.
-
2019Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. CLINICAL LUNG CANCER. E407-E412.Full Text via DOI: 10.1016/j.cllc.2018.12.022 PMID: 30808583
-
2018Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. NEW ENGLAND JOURNAL OF MEDICINE. 379:2342-2350.Full Text via DOI: 10.1056/NEJMoa1809697 PMID: 30280658
-
2018High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. LUNG CANCER. 126:48-54.Full Text via DOI: 10.1016/j.lungcan.2018.08.011 PMID: 30527192
-
2018Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC. JOURNAL OF THORACIC ONCOLOGY. S184-S184.
-
2018Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 36:2251-+.Full Text via DOI: 10.1200/JCO.2017.77.4794 PMID: 29768118
-
2018Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung. JOURNAL OF CLINICAL ONCOLOGY.
-
2018
-
2018Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 81:679-686.Full Text via DOI: 10.1007/s00280-018-3527-6 PMID: 29442139
-
2018EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO PRECISION ONCOLOGY. 2:1-13.Full Text via DOI: 10.1200/PO.17.00116 PMID: 35135111
-
2018Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. LUNG CANCER. 117:38-43.Full Text via DOI: 10.1016/j.lungcan.2018.01.007 PMID: 29496254
-
2017PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 1314-1315.
-
2017Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 377:1919-1929.Full Text via DOI: 10.1056/NEJMoa1709937 PMID: 28885881
-
2017Plasma CfDNA next Generation Sequencing in Non-Small Cell Lung Cancer: Clinical Outcomes and Comparison to Tissue. JOURNAL OF THORACIC ONCOLOGY. S1862-S1862.
-
2017Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report. AMERICAN JOURNAL OF CASE REPORTS. 18:799-804.Full Text via DOI: 10.12659/AJCR.903698 PMID: 28713152
-
2017Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade A Key Player Against Various Cancers. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. 851-861.Full Text via DOI: 10.5858/arpa.2016-0361-RA PMID: 28418281
-
2017B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy. JOURNAL OF CLINICAL ONCOLOGY.Full Text via DOI: 10.1200/JCO.2017.35.15_suppl.TPS9103
-
2017De-escalation of radiotherapy for the treatment of HPV-associated head and neck cancer: A case report and a word of caution. ACTA OTO-LARYNGOLOGICA CASE REPORTS. 2:29-33.Full Text via DOI: 10.1080/23772484.2017.1292399
-
2017Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non Small-Cell Lung Cancer. CLINICAL LUNG CANCER. 18:50-59.Full Text via DOI: 10.1016/j.cllc.2016.09.013 PMID: 27856142
-
2017First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC). CANCER INVESTIGATION. 35:541-546.Full Text via DOI: 10.1080/07357907.2017.1344698 PMID: 28762849
-
2017Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. S378-S378.
-
2016Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. JOURNAL OF CLINICAL ONCOLOGY. 34:2858-+.Full Text via DOI: 10.1200/JCO.2015.63.5888 PMID: 27022118
-
2016Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. JOURNAL OF CLINICAL ONCOLOGY. 34:661-+.Full Text via DOI: 10.1200/JCO.2015.63.9443 PMID: 26598747
-
2016Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. LANCET ONCOLOGY. 17:234-242.Full Text via DOI: 10.1016/S1470-2045(15)00488-X PMID: 26708155
-
2015Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. ONCOLOGIST. 20:1298-1303.Full Text via DOI: 10.1634/theoncologist.2015-0136 PMID: 26306902
-
2015First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer (vol 371, pg 2167, 2014). NEW ENGLAND JOURNAL OF MEDICINE. 1582-1582.Full Text via DOI: 10.1056/NEJMx150034
-
2015Activity of Rociletinib in EGFR Mutant NSCLC Patients with a History of CNS Involvement. JOURNAL OF THORACIC ONCOLOGY. S319-S319.
-
2015Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. EUROPEAN JOURNAL OF CANCER. S598-S598.
-
2015Intracranial Efficacy of First-Line Crizotinib vs. Chemotherapy in ALK-Positive NSCLC. JOURNAL OF THORACIC ONCOLOGY. S377-S377.
-
2015Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC. JOURNAL OF THORACIC ONCOLOGY. S237-S238.
-
2015
-
2015FPGS expression to predict overall survival in non-small cell lung cancer patients treated with pemetrexed.. JOURNAL OF CLINICAL ONCOLOGY.
-
2014First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 371:2167-2177.Full Text via DOI: 10.1056/NEJMoa1408440 PMID: 26466011
-
2014Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. S37-S38.
-
2014FIRST-LINE CRIZOTINIB VS PEMETREXED plus CISPLATIN/CARBOPLATIN IN ASIAN PATIENTS WITH ADVANCED ALK plus NSCLC IN PROFILE 1014. ANNALS OF ONCOLOGY.Full Text via DOI: 10.1093/annonc/mdu395.1
-
2014Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. INVESTIGATIONAL NEW DRUGS. 32:362-368.Full Text via DOI: 10.1007/s10637-013-0061-6 PMID: 24420556
-
2013The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC. CURRENT ONCOLOGY REPORTS. 15:424-432.Full Text via DOI: 10.1007/s11912-013-0330-8 PMID: 23780822
-
2013
-
2013Predictors of outcome for pemetrexed (Pem) in metastatic NSCLC (mNSCLC).. JOURNAL OF CLINICAL ONCOLOGY.
-
2012Thymic Neoplasms: a Clinical Update. CURRENT ONCOLOGY REPORTS. 14:350-358.Full Text via DOI: 10.1007/s11912-012-0246-8 PMID: 22639107
-
2012A strong step forward in maintenance therapy for non-small cell lung cancer treatment. TRANSLATIONAL LUNG CANCER RESEARCH. 99-101.Full Text via DOI: 10.3978/j.issn.2218-6751.2012.04.01 PMID: 25806164
-
2012Current and emerging medical treatments for non-small cell lung cancer: A primer for pulmonologists. RESPIRATORY MEDICINE. 473-492.Full Text via DOI: 10.1016/j.rmed.2011.10.016 PMID: 22119173
-
2012Phase-II Trial of Rebeccamycin Analog, a Dual Topoisomerase-I and -II Inhibitor, in Relapsed "Sensitive" Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 7:751-754.Full Text via DOI: 10.1097/JTO.0b013e31824abca2 PMID: 22425925
-
2012Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 7:137-142.Full Text via DOI: 10.1097/JTO.0b013e318233d80f PMID: 22071780
-
2012Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-alpha in patients with metastatic renal cell carcinoma. BJU INTERNATIONAL. 109:63-69.Full Text via DOI: 10.1111/j.1464-410X.2010.10011.x PMID: 21244601
-
2011A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors. CLINICAL CANCER RESEARCH. 17:7754-7764.Full Text via DOI: 10.1158/1078-0432.CCR-11-1002 PMID: 21976535
-
2011Adjuvant Whole-Brain Radiotherapy Versus Observation after Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study. CURRENT ONCOLOGY REPORTS. 255-258.Full Text via DOI: 10.1007/s11912-011-0180-1 PMID: 21584645
-
2011CORRELATION OF TIMING AND CLINICAL BENEFIT FROM TREATMENT WITH PEMETREXED IN METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC). JOURNAL OF THORACIC ONCOLOGY. S1304-S1305.
-
2011
-
2011
-
2011Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU INTERNATIONAL. 107:562-570.Full Text via DOI: 10.1111/j.1464-410X.2010.09573.x PMID: 20840548
-
2010Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors. DRUG METABOLISM AND DISPOSITION. 38:1962-1966.Full Text via DOI: 10.1124/dmd.110.033951 PMID: 20671097
-
2010Winning the Battle, Losing the War: The Noncurative "Curative" Resection for Stage I Adenocarcinoma of the Lung. ANNALS OF THORACIC SURGERY. 90:1067-1074.Full Text via DOI: 10.1016/j.athoracsur.2010.04.108 PMID: 20868788
-
2010Limited Resection for Early-Stage Lung Cancer. CURRENT ONCOLOGY REPORTS. 285-287.Full Text via DOI: 10.1007/s11912-010-0112-5 PMID: 20652654
-
2010Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression. MOLECULAR CANCER THERAPEUTICS. 9:2309-2321.Full Text via DOI: 10.1158/1535-7163.MCT-10-0309 PMID: 20682643
-
2009GENDER, RACE, AND SURVIVAL: A STUDY IN NON-SMALL-CELL LUNG CANCER BRAIN METASTASES PATIENTS UTILIZING THE RADIATION THERAPY ONCOLOGY GROUP RECURSIVE PARTITIONING ANALYSIS CLASSIFICATION. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 75:1141-1147.Full Text via DOI: 10.1016/j.ijrobp.2008.12.022 PMID: 19327899
-
2009A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors. CLINICAL CANCER RESEARCH. 15:6277-6283.Full Text via DOI: 10.1158/1078-0432.CCR-09-0717 PMID: 19773375
-
2009Small Vessel Ischemic Disease of the Brain and Brain Metastases in Lung Cancer Patients. PLOS ONE. 4.Full Text via DOI: 10.1371/journal.pone.0007242 PMID: 19789633
-
2009A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer The Cleveland Clinic Experience. JOURNAL OF THORACIC ONCOLOGY. 4:976-982.PMID: 19633473
-
2009Investigational Agents in the Management of Non-Small Cell Lung Cancer. CURRENT ONCOLOGY REPORTS. 11:275-284.PMID: 19508832
-
2009A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors. CLINICAL CANCER RESEARCH. 15:2552-2558.Full Text via DOI: 10.1158/1078-0432.CCR-08-1978 PMID: 19318484
-
2009Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy. JOURNAL OF CLINICAL ONCOLOGY. 27:235-241.Full Text via DOI: 10.1200/JCO.2008.18.0000 PMID: 19064974
-
2008Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. INVESTIGATIONAL NEW DRUGS. 26:553-559.Full Text via DOI: 10.1007/s10637-008-9153-0 PMID: 18626572
-
2008Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in Stage III lung cancer: Insights for radiotherapy planning from a surgical cohort. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 72:702-706.Full Text via DOI: 10.1016/j.ijrobp.2008.01.045 PMID: 18374513
-
2008Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. CANCER. 113:1309-1314.Full Text via DOI: 10.1002/cncr.23711 PMID: 18618496
-
2008Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. CLINICAL GENITOURINARY CANCER. 6:79-85.Full Text via DOI: 10.3816/CGC.2008.n.012 PMID: 18824429
-
2008Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 62:347-354.Full Text via DOI: 10.1007/s00280-007-0594-5 PMID: 17909807
-
2008ProApoliploprotein A1 - A serum marker of brain metastases in lung cancer patient. CANCER. 112:1313-1324.Full Text via DOI: 10.1002/cncr.23314 PMID: 18257091
-
2008Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. ANNALS OF ONCOLOGY. 19:265-268.Full Text via DOI: 10.1093/annonc/mdm483 PMID: 17962201
-
2008Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. JOURNAL OF UROLOGY. 179:81-86.Full Text via DOI: 10.1016/j.juro.2007.08.127 PMID: 17997441
-
2007Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array. THORAX. 62:565-568.Full Text via DOI: 10.1136/thx.2006.072892 PMID: 17327260
-
2007Lung cancer screening.. CURRENT ONCOLOGY REPORTS. 265-74.PMID: 17588350
-
2007Lung cancer screening: Is it time for a change in policy?. CLEVELAND CLINIC JOURNAL OF MEDICINE. 74:441-448.PMID: 17569202
-
2007Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid (R)) in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS. 25:211-216.Full Text via DOI: 10.1007/s10637-006-9025-4 PMID: 17103043
-
2007Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. LUNG CANCER. 56:377-381.Full Text via DOI: 10.1016/j.lungcan.2007.01.020 PMID: 17328989
-
2007Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group study 9718. JOURNAL OF THORACIC ONCOLOGY. 2:440-444.PMID: 17473660
-
2007A phase I pharmacokinetic and pharmacodynamic study of S-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. CLINICAL CANCER RESEARCH. 13:2091-2099.Full Text via DOI: 10.1158/1078-0432.CCR-06-1586 PMID: 17404091
-
2007Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. ANNALS OF ONCOLOGY. 18:249-255.Full Text via DOI: 10.1093/annonc/mdl371 PMID: 17060490
-
2007Leg weakness in a 66-year-old woman: A common presentation of an uncommon disease. CLEVELAND CLINIC JOURNAL OF MEDICINE. 23-+.PMID: 17373344
-
2007Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 25:46-52.Full Text via DOI: 10.1016/j.urolonc.2006.02.016 PMID: 17208138
-
2007Validation of the RTOG recursive partitioning analysis (RPA) classification for small-cell lung cancer-only brain metastases. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 67:240-243.Full Text via DOI: 10.1016/j.ijrobp.2006.08.019 PMID: 17056192
-
2006Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. CANCER. 107:2609-2616.Full Text via DOI: 10.1002/cncr.22290 PMID: 17075879
-
2006Phase 1 trial of Anvirzel (TM) in patients with refractory solid tumors. INVESTIGATIONAL NEW DRUGS. 24:423-427.Full Text via DOI: 10.1007/s10637-006-7772-x PMID: 16763787
-
2006Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma. INVESTIGATIONAL NEW DRUGS. 24:321-326.Full Text via DOI: 10.1007/s10637-005-5211-z PMID: 16683075
-
2006Malignant acanthosis nigricans, tripe palms and the sign of Leser-Tre'lat, a hint to the diagnosis of early stage ovarian cancer: A case report and review of the literature. GYNECOLOGIC ONCOLOGY. 101:353-355.Full Text via DOI: 10.1016/j.ygyno.2005.12.024 PMID: 16443260
-
2006Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. ANNALS OF ONCOLOGY. 17:860-865.Full Text via DOI: 10.1093/annonc/mdl010 PMID: 16524966
-
2006Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappa B-independent mechanisms. ANTICANCER RESEARCH. 26:1869-1876.PMID: 16827119
-
2006Phenoxodiol: isoflavone analog with antineoplastic activity.. CURRENT ONCOLOGY REPORTS. 104-7.PMID: 16507219
-
2006Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. MEDICAL ONCOLOGY. 23:507-513.PMID: 17303909
-
2005Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3 sigma and survivin. MOLECULAR CANCER THERAPEUTICS. 4:1880-1890.Full Text via DOI: 10.1158/1535-7163.MCT-05-0222 PMID: 16373703
-
2005The clinical picture - A woman with headache and blurred vision. CLEVELAND CLINIC JOURNAL OF MEDICINE. 848-+.PMID: 16231683
-
2005S100 beta as a predictor of brain metastases - Brain versus cerebrovascular damage. CANCER. 104:817-824.Full Text via DOI: 10.1002/cncr.21220 PMID: 15971200
-
2005Detection of lung cancer by sensor array analyses of exhaled breath. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 171:1286-1291.Full Text via DOI: 10.1164/rccm.200409-1184OC PMID: 15750044
-
2005Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY. 23:832-841.Full Text via DOI: 10.1200/JCO.2005.05.179 PMID: 15681528
-
2004Is lung cancer in the nonsmoker a different disease?. CHEST. 326-329.PMID: 15302708
-
2004Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma. INVESTIGATIONAL NEW DRUGS. 22:277-284.PMID: 15122074
-
2004Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: Phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. JOURNAL OF CLINICAL ONCOLOGY. 22:2891-2900.Full Text via DOI: 10.1200/jco.2004.10.045 PMID: 15254058
-
2003F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY. 21:3995-4000.Full Text via DOI: 10.1200/JCO.2003.04.073 PMID: 14581422
-
2003Renal cell carcinoma (RCC) and telomerase activity: relationship to stage. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 21:424-430.Full Text via DOI: 10.1016/S1078-1439(03)00003-6 PMID: 14693268
-
2003Apoptotic pathways of epothilone BMS 310705. GYNECOLOGIC ONCOLOGY. 91:173-178.Full Text via DOI: 10.1016/S0090-8258(03)00481-5 PMID: 14529678
-
2003An overview of targeted treatments in cancer. CLINICAL THERAPEUTICS. 2121-2137.PMID: 14512124
-
2003Targeted therapy for lung cancer.. CURRENT ONCOLOGY REPORTS. 326-33.PMID: 12781076
-
2003Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: Toxicity and immunological effects. CLINICAL CANCER RESEARCH. 9:1354-1360.PMID: 12684404
-
2003Tubulin interacting agents: novel taxanes and epothilones.. CURRENT ONCOLOGY REPORTS. 89-98.PMID: 12583825
-
2003Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. CANCER. 97:170-178.Full Text via DOI: 10.1002/cncr.10991 PMID: 12491518
-
2002Paclitaxel in cancer therapy.. EXPERT OPINION ON PHARMACOTHERAPY. 755-66.PMID: 12036415
-
2002Acanthosis Nigricans with endometrial carcinoma: Case report and review of the literature. GYNECOLOGIC ONCOLOGY. 84:332-334.Full Text via DOI: 10.1006/gyno.2001.6472 PMID: 11812096
-
2000Interleukin-2 in cancer therapy - Uses and optimum management of adverse effects. BIODRUGS. 299-318.PMID: 18034575
-
2000Longterm outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis. JOURNAL OF RHEUMATOLOGY. 27:1237-1240.PMID: 10813293
Background
Full Name
- Tarek M. Mekhail, MD
Education
- Cairo University Egypt
Residency
- Cleveland Clinic Foundation Ohio
Fellowship
- Cleveland Clinic Foundation Ohio
Board Certification
- American Board of Internal Medicine
Contact
primary email
- Research.Institute@AdventHealth.com